Elevation Oncology, Inc. (ELEV) - Dilution Analysis

POS AM filing: Post-effective amendment to remove unsold securities from registration statements No. 333-265979 and No. 333-279053 due to the completion of a merger.

POS AM filing: Post-Effective Amendment to Registration Statement to remove unsold securities and terminate the effectiveness of the Registration Statement due to a merger.

10-Q filing | 59.2M shares outstanding

10-K filing | 57.3M shares outstanding

10-Q filing | 59.1M shares outstanding

10-Q filing | 59.0M shares outstanding

S-3 filing: This S-3 filing includes a shelf registration for the potential offering of common stock, preferred stock, debt securities, warrants, subscription rights, and units up to an aggregate amount of $350,000,000, the offer and sale from time to time of up to 3,283,862 shares of common stock by selling stockholders, and an at the market offering of common stock up to 75,000,000.00.

10-Q filing | 54.6M shares outstanding

10-K filing | 48.7M shares outstanding

10-Q filing | 42.4M shares outstanding

10-Q filing | 42.4M shares outstanding

8-K filing: Elevation Oncology, Inc. entered into an underwriting agreement to issue and sell 17,810,000 shares of common stock, pre-funded warrants to purchase 4,440,000 shares of common stock and common stock warrants to purchase 22,250,000 shares of common stock, with expected net proceeds of approximately $46.4 million. ($46.4M proceeds)

10-Q filing | 23.6M shares outstanding

10-K filing | 23.3M shares outstanding

10-Q filing | 23.3M shares outstanding

10-Q filing | 23.3M shares outstanding

S-3/A filing: The company may offer up to $250,000,000 aggregate dollar amount of shares of common stock or preferred stock, debt securities, warrants, subscription rights and/or units.

8-K filing: Elevation Oncology entered into a license agreement with CSPC Megalith Biopharmaceutical, a loan agreement with K2 HealthVentures for up to $50 million, and issued a warrant to K2HV to purchase 339,725 shares of common stock at an exercise price of $1.3246.

S-3 filing: The company may offer up to $250,000,000 aggregate dollar amount of shares of its common stock or preferred stock, debt securities, warrants to purchase its common stock, preferred stock or debt securities, subscription rights to purchase its common stock, preferred stock or debt securities and/or units consisting of some or all of these securities. Also registering $19,500,000 of common stock that may be issued and sold under an open market sale agreement dated July 1, 2022 with Cowen and Company, LLC.

10-Q filing | 23.2M shares outstanding

10-K filing | 23.2M shares outstanding

10-Q filing | 23.1M shares outstanding

10-Q filing | 23.2M shares outstanding

S-1/A filing: Elevation Oncology, Inc. is offering 6,250,000 shares of its common stock in an initial public offering, with an expected price between $15.00 and $17.00 per share, and has granted the underwriters an option to purchase up to 937,500 additional shares.

S-1/A filing: Elevation Oncology, Inc. is offering 6,250,000 shares of common stock in an initial public offering, with an option for underwriters to purchase an additional 937,500 shares.

S-1/A filing: This S-1/A filing details the issuance of stock options and restricted common stock to employees, directors, consultants, and other service providers under the 2019 Plan.

S-1 filing: This S-1 filing details a company's initial public offering and the automatic conversion of preferred stock into common stock upon completion of the offering.